Biopharma Data Feeds - Detailed Primer - 867, 844, 852

In the biopharma industry, effective distribution and supply chain management are pivotal to the success of pharmaceutical products. Central to these operations are Electronic Data Interchange (EDI) documents, essential for the flow of information in this intricate network. EDI documents such as EDI 852, EDI 844, and EDI 867, each play critical roles in the distribution process, providing essential data needed for a seamless supply chain.
 

These articles are part of the Gridlex Weekly Newsletter focused on Biopharma technology, analytics, and operational topics. Please email gridlexnewsletter@gridlex21.com to join this newsletter and receive updates (not more than once per week).

These EDI documents are not just about transferring data; they are about translating information into actionable insights. For example, EDI 852 provides deep insights into product activities and market dynamics, while EDI 867 delves into product transfers and resale, offering a microscopic view of the distribution chain. The EDI 844 document stands out for its specific role in managing chargebacks, a crucial aspect in pharmaceutical transactions involving pricing agreements and rebates.
 

However, the utilization of these EDI documents comes with its own set of challenges. Issues like non-standardized data formats can lead to inconsistencies and inefficiencies, while limited data visibility due to incomplete or masked information can hinder decision-making. This primer aims to dissect these EDI documents in detail, revealing their unique functionalities, the challenges they present, and the critical role they play in the biopharma sector. By understanding how to effectively manage these data feeds, biopharma companies can optimize their distribution strategies, maintain robust supply chains, and ultimately ensure the timely delivery of vital pharmaceutical products to the market.

 

1. EDI 852 - Product Activity Data: Critical for Inventory and Market Analysis

The EDI 852 document is instrumental in biopharma distribution, offering detailed insights into product activities crucial for inventory management and market analysis. This document captures comprehensive data that includes:
 

• Item Specifics: EDI 852 comprehensively details each pharmaceutical product, including its descriptions and UPC codes. This granularity is critical in the biopharma industry for accurate product identification and tracking. Detailed item information assists in distinguishing between similar products, effectively managing inventory, and ensuring accurate logistics and distribution.
   

• Sales Data: This segment of EDI 852 provides a dual perspective on sales, offering both monetary values and unit counts. This bifocal view is essential in the biopharma sector, as it reveals not just the revenue generated but also the volume of products moving through the supply chain. It is key for assessing market penetration, understanding sales patterns, and planning production in line with demand trends.
   

• Inventory Status: EDI 852 offers real-time insights into current inventory levels, quantities on order, and received shipments. In biopharma, where inventory management involves considerations like expiration dates and storage conditions, this data is invaluable. It aids in maintaining optimal stock levels, minimizing waste, and ensuring readiness for fluctuating market demands.
   

• Market Dynamics: The document provides deep insights into market trends and product performance. This data is instrumental for biopharma companies in making informed decisions. It enables the analysis of sales trends, assessment of consumer demand, and evaluation of market response to different products. Such insights are critical for tailoring marketing strategies, forecasting market needs, and guiding product development and distribution.

 

Scenario:

In a scenario involving PharmaCorp, a biopharma company, EDI 852 plays a key role in the distribution strategy for a new cardiovascular drug. Utilizing this document, PharmaCorp accurately monitors sales patterns, adjusts inventory at various distribution points, and aligns production with market demand. This data is invaluable for making informed decisions in production planning, marketing strategies, and managing the supply chain efficiently.

 

Challenges with EDI 852:

A major challenge encountered with EDI 852 is the issue of data standardization. Different retailers and distribution centers may use varied data formats and descriptions, posing a challenge for PharmaCorp in consolidating this information into a unified analysis. This lack of standardization can result in inconsistent data interpretation, impacting decision-making processes and responsiveness to market shifts.

 

2. EDI 844 - Product Transfer Account Adjustment

EDI 844 is a key document in the biopharma industry, primarily used for managing financial adjustments such as chargebacks, product returns, and credits. This document ensures accurate financial reconciliation within the supply chain. This document captures comprehensive data that includes:
 

• Chargeback Details: EDI 844 provides a detailed breakdown of each chargeback transaction. This includes comprehensive product identification, which encompasses name, batch number, and expiration date, when relevant. The document also meticulously details the pricing structure for each product, illustrating the wholesale price, the price after contractual adjustments, such as rebates or discounts, and the total chargeback amount due. This level of detail is essential for validating each transaction against the contractual terms agreed upon by manufacturers and wholesalers.
   

• Return and Credit Information: In addition to chargebacks, EDI 844 is instrumental in managing returns and related financial adjustments. It catalogs reasons for product returns, whether due to damage, expiration, recall, or other causes, providing essential context for each financial adjustment. The document quantifies the returned items and executes the necessary credit calculations, ensuring that all financial adjustments are accurately reflected in the accounting records. This process is critical for maintaining accurate inventory levels and ensuring that financial records reflect the current state of transactions.
   

• Financial Accuracy and Compliance: EDI 844 is a key tool in maintaining financial accuracy and adherence to regulatory standards. The document serves as an audit trail for financial transactions, which is vital for regulatory compliance, internal auditing, and resolving disputes. It is crucial for biopharma companies to manage these documents with a high level of precision to avoid legal and compliance issues. Given the sensitive nature of the financial data involved, maintaining the integrity and security of this data is paramount to protect against breaches and ensure confidentiality.
   

Scenario:

Biopharma companies rely on EDI 844 for efficient financial management. For instance, a company like BioHeal Pharmaceuticals may use EDI 844 to process and record financial adjustments stemming from product returns due to expiration or damage. The detailed information provided in EDI 844 helps BioHeal to maintain precise financial records and manage its inventory accurately, ensuring that all financial transactions are accounted for and aligned with contractual agreements.

 

Challenges with EDI 844:

The complexity of managing diverse financial transactions makes EDI 844 a challenging document to handle. Each transaction type, be it a chargeback, return, or credit, comes with its own set of conditions and financial implications. Ensuring accuracy in these transactions is critical to avoid financial discrepancies and maintain integrity in financial reporting and inventory management.

 

3. EDI 867 - Product Transfer and Resale Report in Biopharma

EDI 867 is a pivotal document in the biopharma industry, specifically utilized for providing detailed reports on product movements and resale activities between wholesalers and their downstream customers. This document includes comprehensive data on various aspects of product distribution, offering invaluable insights into supply chain dynamics and market behaviors. The details included in EDI 867 encompass:
 

• Product Transfer Information: EDI 867 provides in-depth information on each phase of the product's transfer within the supply chain. This includes tracking the product's journey from manufacturers to wholesalers and eventually to retailers or healthcare providers. It encompasses the quantities of products shipped, the conditions under which they were transported, and any intermediate stops or handling they underwent. This level of detail is critical for biopharma companies to ensure that their products are being distributed efficiently and safely, adhering to all necessary regulatory standards.
   

• Resale Activity Data: The document offers a detailed view of the resale activities of pharmaceutical products. It captures nuanced data such as the types of healthcare providers or retailers purchasing the products, the frequency of these transactions, and the volume of products being resold. This information is key for understanding the market demand, identifying trends in product sales, and developing targeted marketing and sales strategies.
   

• Invoice-Level Reporting: EDI 867 includes comprehensive invoice-level data, providing a granular view of each transaction. This data includes detailed pricing information, discounts applied, and the final billing amount for each product. Such detailed financial reporting is essential for accurate revenue tracking, financial planning, and ensuring transparency in billing practices.
   

• Timing of Transactions: The timing of each transaction recorded in EDI 867 helps biopharma companies understand the sales cycle of their products. This data is invaluable for forecasting demand, planning inventory restocks, and strategizing product launches. Understanding the temporal patterns of sales can also assist in identifying peak demand periods and adjusting marketing efforts accordingly.

 

Scenario:

A practical application of EDI 867 can be seen in VitalPharm, a biopharma company. They utilize EDI 867 to gain comprehensive insights into the distribution of their medications. The document helps them track how medications move from wholesalers to pharmacies and hospitals, including the quantities sold and the locations of these transactions. This level of detail enables VitalPharm to assess their market penetration, streamline their supply chain, and make informed decisions about production and distribution.

 

Challenges with EDI 867:

Despite its utility, EDI 867 presents challenges, particularly in terms of data completeness and visibility. Wholesalers may restrict access to certain data to protect competitive information, leading to gaps in the data received by manufacturers. This limitation can hinder a comprehensive understanding of the market, affecting strategic decision-making processes. Biopharma companies must navigate these challenges to effectively leverage the insights provided by EDI 867 for supply chain optimization and market analysis.

 

4. 3PL Data in Biopharma Distribution

Third-Party Logistics (3PL) data plays a critical role in the biopharma distribution chain, particularly for products that require specialized handling, like temperature-controlled medications or treatments needing specific storage conditions. 3PL providers such as Cardinal Health, McKesson, AmerisourceBergen, and ICS are central to ensuring the safe and efficient delivery of these sensitive products. These providers offer comprehensive data in an EDI format, which is vital for effectively managing the distribution process. This data includes:
 

• Handling and Storage Information: The handling and storage information provided by 3PL data is vital, especially for temperature-sensitive or fragile biopharma products. This includes detailed guidelines on maintaining specific temperature ranges crucial for preserving drug efficacy, and instructions for handling fragile items to prevent damage during transit. For example, certain biologic drugs may require refrigeration at precise temperatures, while others, like some gene therapies, might need to be frozen. The data also encompasses the necessary precautions to be taken during the loading and unloading of these products, ensuring that they are not exposed to adverse conditions. This level of detail is essential not only for preserving the quality of the products but also for adhering to regulatory standards that govern the safe and effective distribution of pharmaceuticals.
   

• Transportation and Delivery Tracking: 3PL data is instrumental in providing comprehensive transportation and delivery tracking. This includes monitoring the route taken during the transit of pharmaceutical products, ensuring they are moved through conditions that maintain their integrity. Real-time tracking information allows companies to monitor the exact location of their products, anticipate delivery times, and prepare for timely distribution. This aspect of 3PL data is particularly important for time-sensitive drugs or treatments that require immediate delivery upon arrival. Additionally, this tracking capability enables quick response in case of transit delays or rerouting, which is crucial in maintaining the supply chain's reliability and efficiency.
   

• Inventory Level Monitoring: 3PL data offers crucial insights into inventory levels throughout the distribution chain. It provides information on stock levels at warehouses, in transit, and at final delivery points, enabling companies to make informed decisions about stock replenishment and production scaling. For biopharma companies, effective inventory management is key to ensuring that there is no overstock leading to product waste, particularly for drugs with shorter shelf lives, and no understock that could result in supply chain disruptions. This data aids in forecasting demand, planning for production, and optimizing the inventory to meet market requirements efficiently.

 

Scenario:

For instance, with GenTherapeutics, which partners with 3PL providers for distributing its gene therapy treatments. The data received from 3PL providers include specifics on handling, storage, and transportation conditions. This information is critical for GenTherapeutics to ensure that their treatments are distributed under optimal conditions, maintaining product integrity until they reach the end-users.

 

Challenges in Managing 3PL Data:

The complexity of 3PL data and its integration with other data systems presents a significant challenge. Effective management of this data requires specialized tools and expertise. The data encompasses various logistics variables, and companies must ensure compliance with strict regulatory standards throughout the distribution process. Without a robust system to process and interpret this data, biopharma companies like GenTherapeutics could face challenges in maintaining visibility and control over their distribution networks, impacting the overall efficiency of product delivery.

 

How Gridlex CRM Addresses EDI Challenges
 

• Advanced Reporting and Analytics: Gridlex CRM's robust analytics tools are adept at dissecting and visualizing complex datasets from EDI documents, particularly for EDI 852 and EDI 867. This feature plays a crucial role in converting product activity data and resale reports into strategic insights, aiding biopharma companies in making informed decisions regarding market trends, inventory management, and supply chain dynamics.
   

• Customizable Data Fields and Forms: To tackle the challenge of data standardization in EDI 852, Gridlex CRM allows for comprehensive customization. Biopharma companies can tailor their CRM system to align perfectly with varied data formats of EDI documents, ensuring precise capture and organization of critical details like product specifics, pricing structures, and transactional histories, thus enhancing data uniformity and analysis accuracy.
   

• Integrated MDM and Data Engineering: The complexity of financial transactions in EDI 844 and the intricate data handling in EDI 867 are adeptly managed with Gridlex’s MDM capabilities. Features like data versioning and soft merges in Gridlex CRM play a pivotal role in maintaining data integrity and consistency, essential for accurately processing chargebacks, returns, and ensuring compliance with regulatory standards.
   

• Change Deployment with Test Environments: Gridlex CRM offers an innovative solution for adapting to new EDI standards or formats. The system allows for testing changes in a controlled environment, ensuring that updates or modifications to handle various EDI documents are smoothly integrated into existing workflows, thus preventing operational disruptions.
   

• Permission-based Access System: The handling of sensitive EDI data is secured through Gridlex CRM's advanced permissioning system. This feature is vital for safeguarding crucial information, ensuring that access to EDI data is strictly controlled and limited to authorized personnel, a key aspect in maintaining data confidentiality and security, especially in regulatory-sensitive environments.
   

• Sunshine Act, Compliance, and Other Regulatory Integrations: Gridlex CRM’s ability to seamlessly integrate with regulatory compliance tools is especially beneficial for EDI 844 management. It ensures adherence to industry regulations like the Sunshine Act, facilitating compliance in financial transactions or value transfers, and providing an additional layer of oversight and accountability in financial management.